Fonte: European Journal of Pharmaceutical Sciences. Unidade: FCFRP
Assuntos: FÁRMACOS, FARMACOCINÉTICA, MODELAGEM DE DADOS, POLIMORFISMO
ABNT
MOREIRA, Fernanda de Lima et al. Assessing the contribution of UGT isoforms on raltegravir drug disposition through PBPK modeling. European Journal of Pharmaceutical Sciences, v. 179, p. 1-9, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.ejps.2022.106309. Acesso em: 01 dez. 2025.APA
Moreira, F. de L., Tarozzo, M. M. de B., Nardotto, G. H. B., Gonçalves, J. C. S., Schmidt, S., & Moraes, N. V. de. (2022). Assessing the contribution of UGT isoforms on raltegravir drug disposition through PBPK modeling. European Journal of Pharmaceutical Sciences, 179, 1-9. doi:10.1016/j.ejps.2022.106309NLM
Moreira F de L, Tarozzo MM de B, Nardotto GHB, Gonçalves JCS, Schmidt S, Moraes NV de. Assessing the contribution of UGT isoforms on raltegravir drug disposition through PBPK modeling [Internet]. European Journal of Pharmaceutical Sciences. 2022 ; 179 1-9.[citado 2025 dez. 01 ] Available from: https://doi.org/10.1016/j.ejps.2022.106309Vancouver
Moreira F de L, Tarozzo MM de B, Nardotto GHB, Gonçalves JCS, Schmidt S, Moraes NV de. Assessing the contribution of UGT isoforms on raltegravir drug disposition through PBPK modeling [Internet]. European Journal of Pharmaceutical Sciences. 2022 ; 179 1-9.[citado 2025 dez. 01 ] Available from: https://doi.org/10.1016/j.ejps.2022.106309
